Physician profile
Hardeep Singh
NPI 1386708675
$374,339.40
in general payments reported to CMS, 2019-2025
38 companies · $111K in 2025
The $111K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $25K · 2021: $23K · 2022: $45K · 2023: $59K · 2024: $95K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Consulting Fee: $70K · Honoraria: $27K · Travel and Lodging: $17K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,185.00 |
| Consulting Fee | $70,488.00 |
| Honoraria | $26,850.00 |
| Travel and Lodging | $17,132.66 |
| Food and Beverage | $15,194.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $107,500.23 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70,065.15 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $63,162.08 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $44,617.53 | 2024-2025 | Cobenfy |
| Allergan, INC. | $39,812.13 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $31,993.72 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $7,072.96 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $1,258.52 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,243.87 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $1,140.49 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $981.47 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $774.36 | 2020-2025 | Lybalvi, Aristada |
| Validus Pharmaceuticals LLC | $514.13 | 2019-2025 | Raldesy, Equetro |
| Lundbeck LLC | $451.07 | 2019-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $404.76 | 2022-2023 | Quviviq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $371.75 | 2023-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $356.57 | 2019-2022 | |
| Almatica Pharma LLC | $267.75 | 2021-2025 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $262.03 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $238.97 | 2019-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, Lp | $213.33 | 2023-2025 | Adzenys Xr-Odt |
| Corium, LLC | $195.57 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $170.98 | 2019 | |
| Daiichi Sankyo INC. | $169.80 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $161.44 | 2024-2025 | Rejoyn |
| Livanova USA, INC. | $140.71 | 2021 | |
| Braeburn INC. | $124.99 | 2025 | Brixadi |
| Eisai INC. | $109.03 | 2020-2021 | |
| Shire North American Group INC | $100.60 | 2019 | |
| Tris Pharma INC | $98.38 | 2022-2023 | Dyanavel Xr |
| Biogen, INC. | $95.00 | 2023 | |
| Indivior INC. | $88.37 | 2024-2025 | Sublocade |
| Tempus Ai, INC | $80.84 | 2024 | |
| Brainsway USA INC | $36.43 | 2020 | |
| Abbott Laboratories | $21.05 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.60 | 2019 | |
| Merck Sharp & Dohme LLC | $12.92 | 2019 | |
| Bausch Health US, LLC | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.